Express Pharma

DRL launches Tetrabenazine tabs in the US

214

Tetrabenazine Tablets are available in strengths of 12.5 mg and 25 mg, each strength is available in a bottle count size of 112

Dr Reddy’s Laboratories (DRL) has launched Tetrabenazine tablets, a therapeutic equivalent generic version of Xenazine (tetrabenazine) in the US market approved by the US Food and Drug Administration (US FDA).

The Xenazine brand and generic had US sales of approximately $322 million MAT for the most recent twelve months ending in November 2017 according to IMS Health.

Tetrabenazine Tablets are available in strengths of 12.5 mg and 25 mg, each strength is available in a bottle count size of 112.

Xenazine is a registered trademark of Valeant Pharmaceuticals Luxembourg.

- Advertisement -

Comments are closed.